A

ACADIA Pharmaceuticals
D

ACAD

16.115
USD
-0.50
(-2.98%)
Market Closed
Volume
42,068
EPS
0
Div Yield
-
P/E
12
Market Cap
2,687,796,951
OverviewSignalsIdeasNews
Related Instruments
ABBV
ABBV
-3.525
(-1.72%)
201.565 USD
ALNY
ALNY
-4.62
(-1.73%)
262.41 USD
AMGN
AMGN
4.42
(1.45%)
310.04 USD
BIIB
BIIB
-0.630
(-0.48%)
130.690 USD
BMRN
BMRN
-0.810
(-1.19%)
67.490 USD
INCY
INCY
0.180
(0.29%)
62.500 USD
NBIX
NBIX
-5.350
(-4.94%)
102.910 USD
S
SAGE
-0.41000
(-5.27%)
7.37500 USD
S
SRPT
-3.820
(-6.11%)
58.670 USD
X
XNCR
-0.92000
(-9.37%)
8.90000 USD
More
News
Treasury Yields Decline as Market Anticipates Fed Rate Cuts

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

7 months ago
Economy News
Bank of Canada Cuts Rates as Inflation Eases

Bank of Canada Cuts Rates as Inflation Eases

9 months ago
Economy News
Novo Nordisk Surges in Profit and Sales

Novo Nordisk Surges in Profit and Sales

11 months ago
Stocks News
More

Title: ACADIA Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Trading. Social. Simple.
FacebookTwitterYoutube
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHelp Center
Social Network
The NetworkSignals NetworkIdeas NetworkBest Traders
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.